# Artifacts Summary - Onconova Implementation Guide v0.2.0

* [**Table of Contents**](toc.md)
* **Artifacts Summary**

## Artifacts Summary

This page provides a list of the FHIR artifacts defined as part of this implementation guide.

### Requirements: Actor Definitions 

The following artifacts define the types of individuals and/or systems that will interact as part of the use cases covered by this implementation guide.

| | |
| :--- | :--- |
| [Consumer (Onconova)](ActorDefinition-onconova-consumer.md) | An actor representing a data consumer that interacts with the Onconova FHIR REST server to retrieve and read patient case data. |
| [Creator (Onconova)](ActorDefinition-onconova-creator.md) | An actor representing a data creator that interacts with the Onconova FHIR REST server to create and update patient case data. |

### Behavior: Capability Statements 

The following artifacts define the specific capabilities that different types of systems are expected to have in order to comply with this implementation guide. Systems conforming to this implementation guide are expected to declare conformance to one or more of the following capability statements.

| | |
| :--- | :--- |
| [Onconova FHIR REST Server Capability Statement](CapabilityStatement-onconova-capability-statement.md) | Supports the retrieval of the[mCODE Patient Bundle](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-patient-bundle)containing all relevant mCODE resources (provided by Onconova) for a given patient. It also supports CRUD interactions on all Onconova profiles defined in this Implementation Guide. |

### Structures: Resource Profiles 

These define constraints on FHIR resources for systems conforming to this implementation guide.

| | |
| :--- | :--- |
| [Adverse Event Profile](StructureDefinition-onconova-adverse-event.md) | A profile representing an adverse event experienced by a cancer patient as a result of an antineoplastic treatment, structured according to the Common Terminology Criteria for Adverse Events (CTCAE). This resource is used to capture and standardize the documentation of adverse events occurring during cancer care, including the type of event, its CTCAE grade, and any mitigation actions taken.The profile constrains the base FHIR`AdverseEvent`resource to ensure consistent use of CTCAE codes and grades, and supports linkage to related treatments such as medications, radiotherapy, or surgical procedures documented in Onconova. The profile also provides extensions for recording mitigation strategies, supporting detailed tracking and management of adverse events in cancer patients.**Conformance:**AdverseEvent resources representing an adverse event caused by a cancer therapy in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Aneuploid Score Profile](StructureDefinition-onconova-aneuploid-score.md) | A profile representing aneuploid score for a cancer patient.This profile extends the GenomicsReporting IG[GenomicsBase profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-base)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing an aneuploid score obtained through genomic testing in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Cancer Family Member History Profile](StructureDefinition-onconova-cancer-family-member-history.md) | A profile recording of a patient's family member's history of cancer.This profile is based on the core FHIR`FamilyMemberHistory`resource rather than the mCODE[HistoryOfMetastaticCancer profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-history-of-metastatic-cancer)to allow for a broader range of cancer history documentation (not limited to metastatic cancer). It includes constraints to ensure that at least one cancer condition is recorded, along with optional extensions for cancer morphology and topography.**Conformance:**FamilyMemberHistory resources representing a history of (primary or metastatic) cancer in a patient's family member in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Cancer Patient Profile](StructureDefinition-onconova-cancer-patient.md) | A profile representing a patient with or is receiving medical treatment for a malignant growth or tumor.It constrains the mCODE[CancerPatient profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-patient)with specific extensions and constraints for the Onconova use case. Any`Patient`resource complying with the US Core`Patient`or mCODE`CancerPatient`profiles will also comply with this profile if the`Must-Support`extensions are accounted for.**Conformance:**Patient resources representing Cancer Patients in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Cancer Risk Assessment Profile](StructureDefinition-onconova-cancer-risk-assessment.md) | A profile representing a risk assessment performed for a cancer patient, including the method used, the resulting risk level, and an optional numerical score.It constraints the mCODE[CancerRiskAssessment profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-risk-assessment)and expands the valuesets for cancer risk assessment methods and values.**Conformance:**Observation resources representing a cancer-related risk assessment in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Cancer Stage Profile](StructureDefinition-onconova-cancer-stage.md) | A profile representing the cancer stage for a cancer patient.It constrains the mCODE[CancerStage profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-stage)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a cancer staging in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Comorbidities Profile](StructureDefinition-onconova-comorbidities.md) | A profile representing comorbidities for a cancer patient, i.e. other health conditions that exist alongside the primary cancer diagnosis. Supports existing comorbidity panels such as the Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI) with comorbidity indexes.The profile constrains the mCODE[Comorbidities profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-comorbidities)to ensure consistent use of ICD-10 codes for documenting comorbid conditions, and to link the comorbidity information to the Onconova primary cancer condition profile.**Conformance:**Observation resources representing a generic or panel comorbidities assessment in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [ECOG Performance Status Profile](StructureDefinition-onconova-ecog-performance-status.md) | A profile representing the (Eastern Cooperative Oncology Group) ECOG performance status score for a cancer patient.Adds minimal constraints to the mCODE[`ECOGPerformanceStatus`profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-ecog-performance-status)to account for Onconova specifics.**Conformance:**Observation resources representing an ECOG performance status score in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Genomic Variant Profile](StructureDefinition-onconova-genomic-variant.md) | A profile representing a genomic variant identified for a cancer patient.This profile extends the base mCODE[GenomicVariant profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-genomic-variant)(which in turn profiles the Genomics Reporting[Variant profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/variant)) to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a genomic variant in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Homologous Recombination Deficiency Profile](StructureDefinition-onconova-homologous-recombination-deficiency.md) | A profile representing homologous recombination deficiency for a cancer patient.This profile extends the GenomicsReporting IG[GenomicsBase profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-base)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a homologous recombination deficiency obtained through genomic testing in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Imaging Disease Status Profile](StructureDefinition-onconova-imaging-disease-status.md) | A profile representing the imaging-based disease status of a cancer patient.It constrains the mCODE[CancerDiseaseStatus profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-disease-status)to restrict it to imaging-based monitoring evaluated based on RECIST criteria.**Conformance:**Observation resources representing a disease status obtained through imaging techniques in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Karnofsky Performance Status Profile](StructureDefinition-onconova-karnofsky-performance-status.md) | A profile representing the Karnofsky performance status score for a cancer patient.Adds minimal constraints to the mCODE[`KarnofskyPerformanceStatus`profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-karnofsky-performance-status)to account for Onconova specifics.**Conformance:**Observation resources representing a Karnofsky performance status score in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Lifestyle Profile](StructureDefinition-onconova-lifestyle.md) | A profile representing a (reported) observation on certain lifestyle characteristics of a cancer patient (e.g. smoking, drinking, and sleeping habits, environmental exposures, etc.).It directly profiles the base FHIR`Observation`resource as this resource is not represented in mCODE, to add relevant observation components for the different lifestyle characteristics.**Conformance:**Observation resources representing a summary of a patient's lifestyle in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Loss of Heterozygosity Profile](StructureDefinition-onconova-loss-of-heterozygosity.md) | A profile representing loss of heterozygosity for a cancer patient.This profile extends the GenomicsReporting IG[GenomicsBase profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-base)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a loss of heterozygosity obtained through genomic testing in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Lymphoma Stage](StructureDefinition-onconova-lymphoma-stage.md) | Staging of lymphoma (both Hodgkins and Non-Hodgkins) by Ann Arbor, Cotswold, or Lugano staging systems. The method (required) indicates which of these related staging systems was used.**Conformance:**Observation resources representing a lymphoma staging in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Medication Administration Profile](StructureDefinition-onconova-medication-administration.md) | A profile representing a medication administered to a cancer patient during a systemic therapy (e.g., chemotherapy, immunotherapy), including details about the medication and dosage.This profile extends the base mCODE[CancerRelatedMedicationAdministration profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration)to introduce additional information about the systemic therapy (e.g. number of cycles, therapeutic role, etc.) and to introduce references to other medication administration given simultaneously to represent combination therapies.Since Onocnova treats systemic therapies involving multiple antineoplastic agents administered together or in sequence as part of a single treatment plan, this profile allows for capturing such relationships between medication administrations using the`MedicationAdministration.extension[combinedWith]`extension slices.**Conformance:**MedicationAdministration resources representing a systemic therapy in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Microsatellite Instability Profile](StructureDefinition-onconova-microsatellite-instability.md) | A profile representing microsatellite instability for a cancer patient.This profile extends the GenomicsReporting IG[MicrosatelliteInstability profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/msi)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a microsatellite instability obtained through genomic testing in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Molecular Tumor Board Review Profile](StructureDefinition-onconova-molecular-tumor-board-review.md) | A profile representing a specialized molecular tumor board review for a cancer patient. This profile extends the`OnconovaTumorBoardReview`profile to specify that the review is focused on molecular diagnostics and recommendations.**Conformance:**Procedure resources representing a molecular tumor board review in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Primary Cancer Condition Profile](StructureDefinition-onconova-primary-cancer-condition.md) | A profile that records the primary cancer condition, the original or first neoplasm in the body (Definition from:[NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/primary-tumor)). Cancers that are not clearly secondary (i.e., of uncertain origin or behavior) should be documented as primary.It constrains the mCODE[PrimaryCancerCondition profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-primary-cancer-condition)to constrain the terminologies of the cancer topography and morphology extensions to use exclusively ICD-O-3 codes.Local and regional recurrences are indicated using the`clinicalStatus`and`clinicalStatus.extension`to denote that the condition is a recurrence of a previous condition, and to specify the type of recurrence (local or regional).**Conformance:**Condition resources representing a primary or recurrent neoplastic entity in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Radiotherapy Summary Profile](StructureDefinition-onconova-radiotherapy-summary.md) | A profile representing a summary of a course of radiotherapy delivered to a patient. It records the treatment intent, termination reason, modalities, techniques, number of sessions, and doses delivered to one or more body volumes. Whether the course has been fully delivered or stopped is indicated in the status element.This profile extends the base mCODE[RadiotherapyCourseSummary profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-radiotherapy-course-summary)to include specific constraints and requirements for Onconova.**Conformance:**Procedure resources representing a radiotherapy in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Secondary Cancer Condition Profile](StructureDefinition-onconova-secondary-cancer-condition.md) | A profile recording the a secondary neoplasm, including location and the date of onset of metastases. A secondary cancer results from the spread (metastasization) of cancer from its original site (Definition from: NCI Dictionary of Cancer Terms).It constrains the mCODE[SecondaryCancerCCondition profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-secondary-cancer-condition)to constrain the terminologies of the cancer topography and morphology extensions to use exclusively ICD-O-3 codes.**Conformance:**Condition resources representing a metastatic neoplastic entity in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Surgical Procedure Profile](StructureDefinition-onconova-surgical-procedure.md) | A profile representing a surgical procedure performed on a cancer patient, including details about the procedure, its intent, and relevant dates.It extends the base mCODE[CancerRelatedSurgicalProcedure profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-surgical-procedure)to include specific constraints and requirements for Onconova.**Conformance:**Procedure resources representing a surgery in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Distant Metastases Category Profile](StructureDefinition-onconova-tnm-distant-metastases-category.md) | A profile representing the TNM distant metastases category for a cancer patient.This profile extends the base mCODE[TNMDistantMetastasesCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-distant-metastases-category)to include specific constraints and extensions relevant to Onconova. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging distant metastases parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Grade Category Profile](StructureDefinition-onconova-tnm-grade-category.md) | A profile representing the TNM grade category for a cancer patient.This profile extends the base mCODE[TNMCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-category)to specify the new TNM category. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging grade category parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Lymphatic Invasion Category Profile](StructureDefinition-onconova-tnm-lymphatic-invasion-category.md) | A profile representing the TNM lymphatic invasion category for a cancer patient.This profile extends the base mCODE[TNMCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-category)to specify the new TNM category. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging lymphatic invasion parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Perineural Invasion Category Profile](StructureDefinition-onconova-tnm-perineural-invasion-category.md) | A profile representing the TNM perineural invasion category for a cancer patient.This profile extends the base mCODE[TNMCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-category)to specify the new TNM category. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging perineural invasion parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Primary Tumor Category Profile](StructureDefinition-onconova-tnm-primary-tumor-category.md) | A profile representing the TNM primary tumor category for a cancer patient.This profile extends the base mCODE[TNMPrimaryTumorCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-primary-tumor-category)to include specific constraints and extensions relevant to Onconova. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging primary tumor parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Regional Nodes Category Profile](StructureDefinition-onconova-tnm-regional-nodes-category.md) | A profile representing the TNM regional nodes category for a cancer patient.This profile extends the base mCODE[TNMRegionalNodesCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-regional-nodes-category)to include specific constraints and extensions relevant to Onconova. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging regional nodes parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Residual Tumor Category Profile](StructureDefinition-onconova-tnm-residual-tumor-category.md) | A profile representing the TNM residual tumor category for a cancer patient.This profile extends the base mCODE[TNMCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-category)to specify the new TNM category. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging residual tumor parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Serum Tumor Marker Level Category Profile](StructureDefinition-onconova-tnm-serum-tumor-marker-level-category.md) | A profile representing the TNM serum tumor marker level category for a cancer patient.This profile extends the base mCODE[TNMCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-category)to specify the new TNM category. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging serum tumor marker level parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Stage Group](StructureDefinition-onconova-tnm-stage-group.md) | A profile representing the TNM stage group for a cancer patient.It extends the base mCODE[TNMStageGroup profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-stage-group)to expand the TNM subcategories and include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a cancer TNM staging in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [TNM Venous Invasion Category Profile](StructureDefinition-onconova-tnm-venous-invasion-category.md) | A profile representing the TNM venous invasion category for a cancer patient.This profile extends the base mCODE[TNMCategory profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tnm-category)to specify the new TNM category. Onconova does not provide this resource as an independent resource and is expected to be provided as a contained resource in the`TNMStageGroup`profile under`Obseration.contained`.**Conformance:**Observation resources representing a TNM staging venous invasion parameter in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Therapy Line Profile](StructureDefinition-onconova-therapy-line.md) | A profile representing a line of therapy in a cancer treatment regimen, including details about the therapy line number, associated treatments, and relevant dates.Due to its abstract conceptual nature, it is based on a FHIR`List`to capture the specific resources involved in the therapy line. Therapy lines in Onconova are assigned automatically based on existing Procedure and MedicationAdministration resources and are not created manually.**Conformance:**List resources representing a therapy line in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Tumor Board Review Profile](StructureDefinition-onconova-tumor-board-review.md) | A profile representing a tumor board review for a cancer patient.This profile extends the base FHIR`Procedure`resource since there is no equivalent mCODE profile that covers the use case.**Conformance:**Procedure resources representing a tumor board review in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Tumor Marker Profile](StructureDefinition-onconova-tumor-marker.md) | A profile representing a tumor marker observation for a cancer patient, including the type of tumor marker and its value.This profile extends the base mCODE[TumorMarkerTest profile](http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-tumor-marker-test)to include specific constraints and requirements for Onconova.If relied on the same use context as mCODE, namely for substances found in tissue or blood or other body fluids that may be a sign of cancer or certain benign (non-cancer) conditions measured at the levels of the protein and substance post-RNA protein synthesis (not at genomic level).**Conformance:**Observation resources representing a tumor marker in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Tumor Mutational Burden Profile](StructureDefinition-onconova-tumor-mutational-burden.md) | A profile representing tumor mutational burden for a cancer patient.This profile extends the GenomicsReporting IG[TumorMutationalBurden profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/tmb)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a tumor mutational burden obtained through genomic testing in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |
| [Tumor Neoantigen Burden Profile](StructureDefinition-onconova-tumor-neoantigen-burden.md) | A profile representing tumor neoantigen burden for a cancer patient.This profile extends the GenomicsReporting IG[GenomicsBase profile](http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomics-base)to include specific constraints and extensions relevant to Onconova.**Conformance:**Observation resources representing a tumor neoantigen burden obtained through genomic testing in the scope of Onconova SHALL conform to this profile. Any resource intended to conform to this profile SHOULD populate`meta.profile`accordingly. |

### Structures: Extension Definitions 

These define constraints on FHIR data types for systems conforming to this implementation guide.

| | |
| :--- | :--- |
| [Adverse Event Mitigation](StructureDefinition-onconova-ext-adverse-event-mitigation.md) | Details about an action taken to mitigate or manage the adverse event. |
| [CTCAE Grade](StructureDefinition-onconova-ext-adverse-event-ctc-grade.md) | The grade of the adverse event as defined by the Common Terminology Criteria for Adverse Events (CTCAE). |
| [Cancer Patient Age](StructureDefinition-onconova-ext-cancer-patient-age.md) | The approximate age of the patient. |
| [Cancer Patient Age at Diagnosis](StructureDefinition-onconova-ext-cancer-patient-age-at-diagnosis.md) | The approximate age of the patient at the time of diagnosis of the disease. |
| [Cancer Patient Cause of Death](StructureDefinition-onconova-ext-cancer-patient-cause-of-death.md) | The cause of death for the patient. |
| [Cancer Patient Consent status](StructureDefinition-onconova-ext-cancer-patient-consent-status.md) | The status of whether the patient has given or revoked consent for research use. |
| [Cancer Patient Data Completion Rate](StructureDefinition-onconova-ext-cancer-patient-data-completion-rate.md) | The percentage of data elements categories that have been completed for a patient. |
| [Cancer Patient Data Contributors](StructureDefinition-onconova-ext-cancer-patient-data-contributors.md) | The individuals or organizations that contributed to the patient's case data collection. |
| [Cancer Patient End of Records](StructureDefinition-onconova-ext-cancer-patient-end-of-records.md) | Indicates the last known record date of a patient. |
| [Cancer Patient Overall Survival](StructureDefinition-onconova-ext-cancer-patient-overall-survival.md) | The duration of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works. |
| [Cancer Patient Vital status](StructureDefinition-onconova-ext-cancer-patient-vital-status.md) | The status of whether the patient is alive or deceased or unknown. |
| [Cancer Stage Breslow Depth](StructureDefinition-onconova-ext-cancer-stage-breslow-depth.md) | The actual measured Breslow depth as a quantity |
| [Family Member History Cancer Morphology](StructureDefinition-onconova-ext-family-history-member-cancer-morphology.md) | The morphology of a historical cancer associated to a family member of a patient, represented by an ICD-O-3 code. |
| [Family Member History Cancer Topography](StructureDefinition-onconova-ext-family-history-member-cancer-topography.md) | The topography of a historical cancer associated to a family member of a patient, represented by an ICD-O-3 code. |
| [Genomic Variant Assessment Date](StructureDefinition-onconova-ext-genomic-variant-assessment-date.md) | Date at which the genomic variant was assessed and/or reported. |
| [Histological Differentiation](StructureDefinition-onconova-ext-histological-differentiation.md) | The histological differentiation of the tumor. |
| [Homologous Recombination Deficiency Interpretation](StructureDefinition-onconova-ext-homologous-recombination-deficiency-interpretation.md) | The categorical classification of the HRD status interpreted from its value. |
| [Medication Administration Adjunctive Role](StructureDefinition-onconova-ext-medication-administration-adjunctive-role.md) | Indicates the role of this medication administration in the context of the overall treatment plan. |
| [Medication Administration Combined With](StructureDefinition-onconova-ext-medication-administration-combined-with.md) | Indicates which medication administrations were given in combination with the current medication administration. |
| [Medication Administration Cycles](StructureDefinition-onconova-ext-medication-administration-cycles.md) | Indicates the total number of cycles for this medication administration. |
| [Medication Administration Is Primary Therapy](StructureDefinition-onconova-ext-medication-administration-is-primary-therapy.md) | Indicates whether this medication administration is the primary therapy within a therapy line. |
| [Molecular Tumor Board CUP Characterization](StructureDefinition-onconova-ext-molecular-tumor-board-cup-characterization.md) | A characterization of the tumor board review focused on cancer of unknown primary (CUP) origin. |
| [Molecular Tumor Board Molecular Comparison](StructureDefinition-onconova-ext-molecular-tumor-board-molecular-comparison.md) | A comparison of molecular findings discussed during the molecular tumor board review. |
| [Molecular Tumor Board Therapeutic Recommendation](StructureDefinition-onconova-ext-molecular-tumor-board-therapeutic-recommendation.md) | A therapeutic recommendation or follow-up action resulting from a molecular tumor board review. |
| [Primary Cancer Recurrence Of](StructureDefinition-onconova-ext-primary-cancer-recurrence-of.md) | Indicates that the condition is a recurrence of a previous condition, and provides a reference to that previous condition. |
| [Primary Cancer Recurrence Type](StructureDefinition-onconova-ext-primary-cancer-recurrence-type.md) | Indicates the type of recurrence for the condition (local or regional). |
| [Risk Assessment Score](StructureDefinition-onconova-ext-risk-assessment-score.md) | The numerical score of the risk assessment. |
| [Therapy Line Intent](StructureDefinition-onconova-ext-therapy-line-intent.md) | The intent of the therapy line, such as curative or palliative. |
| [Therapy Line Number](StructureDefinition-onconova-ext-therapy-line-number.md) | The number representing the sequence of the therapy line in the overall treatment regimen. |
| [Therapy Line Period](StructureDefinition-onconova-ext-therapy-line-period.md) | The period during which the therapy line was performed. |
| [Therapy Line Progression Date](StructureDefinition-onconova-ext-therapy-line-progression-date.md) | The date when disease progression was observed during or after the therapy line. |
| [Therapy Line Progression-Free Survival](StructureDefinition-onconova-ext-therapy-line-progression-free-survival.md) | The progression-free survival duration for the therapy line. |
| [Therapy Line Reference](StructureDefinition-onconova-ext-therapy-line-reference.md) | A reference to the therapy line associated with this treatment. |
| [Treatment Response RECIST Is Interpreted](StructureDefinition-onconova-ext-treatment-response-recist-is-interpreted.md) | Indicates that whether the RECIST was interpreted from a radiology report rather than extracted. |
| [Tumor Board Specialization](StructureDefinition-onconova-ext-tumor-board-specialization.md) | The specialization or focus area of the tumor board conducting the review, such as hematologic malignancies or solid tumors. |
| [Tumor Marker Analyte](StructureDefinition-onconova-ext-tumor-marker-analyte.md) | The specific analyte or substance being measured as a tumor marker, such as PSA, CA-125, or CEA. |
| [Tumor Mutational Burden Status](StructureDefinition-onconova-ext-tumor-mutational-burden-status.md) | The categorical classification of the TMB status interpreted from its value. |

### Terminology: Value Sets 

These define sets of codes used by systems conforming to this implementation guide.

| | |
| :--- | :--- |
| [Adjunctive Therapy Roles Value Set](ValueSet-onconova-vs-adjunctive-therapy-roles.md) | Codes representing roles for adjunctive therapy in oncology. |
| [Adverse Event Mitigation Categories Value Set](ValueSet-onconova-vs-adverse-event-mitigation-categories.md) | Categories of actions taken to mitigate or manage adverse events in oncology. |
| [Adverse Event Mitigation Drugs Value Set](ValueSet-onconova-vs-adverse-event-mitigation-drugs.md) | Drugs or medication categories used in the mitigation process of an adverse event. |
| [Adverse Event Mitigation Managements Value Set](ValueSet-onconova-vs-adverse-event-mitigation-managements.md) | Classification of actions to mitigate adverse events affecting a patient's health. |
| [Adverse Event Mitigation Procedures Value Set](ValueSet-onconova-vs-adverse-event-mitigation-procedures.md) | Procedures undertaken to mitigate the impact of an adverse event on a patient's health. |
| [Adverse Event Mitigation Treatment Adjustments Value Set](ValueSet-onconova-vs-adverse-event-mitigation-treatment-adjustments.md) | Adjustments made to a patient's treatment plan in response to an adverse event. |
| [Amino Acid Change Type Value Set](ValueSet-onconova-vs-amino-acid-change-types.md) | Amino acid change types due to a genomic variant. It constraints and expands the original[LOINC Answer List LL380-7](https://loinc.org/LL380-7/)to enforce Onconova-compatible codes |
| [Antineoplastic Agents Value Set](ValueSet-onconova-vs-antineoplastic-agents.md) | Drugs and biological agents used in the treatment of neoplastic diseases. |
| [CTC Adverse Events Value Set](ValueSet-onconova-vs-ctc-adverse-events.md) | Adverse events classified according to the Common Terminology Criteria for Adverse Events (CTCAE) |
| [Cancer Imaging Methods Value Set](ValueSet-onconova-vs-cancer-imaging-methods.md) | Imaging methods used in cancer diagnosis and monitoring. |
| [Cancer Risk Assessment Methods Value Set](ValueSet-onconova-vs-cancer-risk-assessment-methods.md) | A value set containing codes for various cancer risk assessment methods. |
| [Cause of Death Value Set](ValueSet-onconova-vs-causes-of-death.md) | The causes of death that are relevant for a cancer patient. |
| [Clinical Relevance Value Set](ValueSet-onconova-vs-clinical-relevances.md) | Categorizations of the clinical relevance of a genomic variant |
| [Coding DNA Change Types Value Set](ValueSet-onconova-vs-dna-change-types.md) | Coding DNA change types due to a genomic variant. It constraints and expands the original[LOINC Answer List LL380-7](https://loinc.org/LL380-7/)to enforce Onconova-compatible codes |
| [Comorbidity Panels Value Set](ValueSet-onconova-vs-comorbidity-panels.md) | A collection of comorbidity panels relevant to cancer patients. |
| [Consent Status Value Set](ValueSet-onconova-vs-consent-status.md) | The consent status of a patient for further use of data in research. |
| [Expected Drug Effects Value Set](ValueSet-onconova-vs-expected-drug-effects.md) | Collection of expected effects when a drug is administered. |
| [Exposure Agents Value Set](ValueSet-onconova-vs-exposure-agents.md) | Agents to which a patient may have been exposed. |
| [Homologous Recombination Deficiency Interpretation Value Set](ValueSet-onconova-vs-homologous-recombination-deficiency-interpretations.md) | The categorical classifications of the HRD status interpreted from its value.. |
| [ICD-10 Codes Value Set](ValueSet-onconova-vs-icd-10-conditions.md) | All possible ICD-10 codes for conditions. |
| [ICD-O-3 Differentiations Value Set](ValueSet-onconova-vs-icdo3-differentiations.md) | The subset of ICD-O-3 concepts dedicated for describing morphology differentiations. |
| [ICD-O-3 Morphology Behavior Value Set](ValueSet-onconova-vs-icdo3-morphology-behaviors.md) | The subset of ICD-O-3 concepts dedicated for describing morphology behavior. |
| [ICD-O-3 Topographies Value Set](ValueSet-onconova-vs-icdo3-topographies.md) | The subset of ICD-O-3 concepts dedicated for describing morphology topographies. |
| [Observation Body Sites Value Set](ValueSet-onconova-vs-observation-bodysites.md) | Bodysites related to an observation |
| [Recreational Drugs Value Set](ValueSet-onconova-vs-recreational-drugs.md) | Substances that people use to alter their mental state, often for pleasure or leisure, with effects ranging from relaxation and euphoria to hallucinations and altered perceptions. |
| [Recurrence Types Value Set](ValueSet-onconova-vs-recurrence-types.md) | A value set representing the types of cancer recurrence, specifically local and regional recurrences. |
| [Risk Assessment Values Value Set](ValueSet-onconova-vs-cancer-risk-assessment-values.md) | A non-exhaustive value set containing codes that result from risk assessments, i.e., the risk level of the cancer. |
| [Smoking status Value Set](ValueSet-onconova-vs-smoking-status.md) | Smoking status of a patient |
| [Surgical Procedures Value Set](ValueSet-onconova-vs-surgical-procedures.md) | Set of surgical procedures relevant to cancer treatment in Onconova. |
| [TNM Distant Metastasis Categories Value Set](ValueSet-onconova-vs-tnm-distant-metastasis-categories.md) | TNM Distant Metastasis Categories Value Set |
| [TNM Grade Categories Value Set](ValueSet-onconova-vs-tnm-grade-categories.md) | TNM Grade Categories Value Set |
| [TNM Grade Category Methods Value Set](ValueSet-onconova-vs-tnm-grade-category-methods.md) | TNM Grade Category Methods Value Set |
| [TNM Lymphatic Invasion Categories Value Set](ValueSet-onconova-tnm-lymphatic-invasion-categories.md) | TNM Lymphatic Invasion Categories Value Set |
| [TNM Perineural Invasion Categories Value Set](ValueSet-onconova-tnm-perineural-invasion-categories.md) | TNM Perineural Invasion Categories Value Set |
| [TNM Primary Tumor Categories Value Set](ValueSet-onconova-vs-tnm-primary-tumor-categories.md) | TNM Primary Tumor Categories Value Set |
| [TNM Regional Nodes Categories Value Set](ValueSet-onconova-vs-tnm-regional-nodes-categories.md) | TNM Regional Nodes Categories Value Set |
| [TNM Residual Tumor Categories Value Set](ValueSet-onconova-tnm-residual-tumor-categories.md) | TNM Residual Tumor Categories Value Set |
| [TNM Serum Tumor Marker Level Categories Value Set](ValueSet-onconova-vs-tnm-serum-tumor-marker-level-categories.md) | TNM Serum Tumor Marker Level Categories Value Set |
| [TNM Venous Invasion Categories Value Set](ValueSet-onconova-vs-tnm-venous-invasion-categories.md) | TNM Venous Invasion Categories Value Set |
| [Treatment Intents Value Set](ValueSet-onconova-vs-treatment-intents.md) | A set of intents for giving a treatment to a cancer patient |
| [Treatment Termination Reasons Value Set](ValueSet-onconova-vs-treatment-termination-reasons.md) | Reasons for terminating a treatment in oncology. |
| [Tumor Board Recommendations Value Set](ValueSet-onconova-vs-tumor-board-recommendations.md) | Recommendations that may be made by a tumor board for a cancer patient. |
| [Tumor Marker Analytes Value Set](ValueSet-onconova-vs-tumor-marker-analytes.md) | Analytes considered tumor markers. |
| [Tumor Marker Tests](ValueSet-onconova-vs-tumor-marker-tests.md) | ValueSet containing LOINC and NCI Thesaurus codes for tumor marker laboratory tests and measurements |
| [Tumor Mutational Burden Status Interpretation Value Set](ValueSet-onconova-vs-tumor-mutational-burden-status-interpretations.md) | The categorical classifications of the TMB status interpreted from its value.. |
| [Vital Status Value Set](ValueSet-onconova-vs-vital-status.md) | The vital status of a patient |

### Terminology: Code Systems 

These define new code systems used by systems conforming to this implementation guide.

| | |
| :--- | :--- |
| [Comorbidity Panels Code System](CodeSystem-onconova-cs-comorbidity-panels.md) | A code system for comorbidity panels relevant to cancer patients. |
| [Consent Status Code System](CodeSystem-onconova-cs-consent-status.md) | A code system for consent status relevant to Onconova patients. |
| [To Be Determined Codes](CodeSystem-onconova-cs-tbd.md) | A code system for codes that are yet to be determined. |

